Quantcast

Latest Boehringer Ingelheim Stories

2014-04-02 04:21:07

LAUSANNE, Switzerland and HAMBURG, Germany, April 2, 2014 /PRNewswire/ -- - Innovative partnership based on Evotec's Target X projects - Evotec and Debiopharm to share discovery and development efforts Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today a research collaboration and licensing deal with Debiopharm Group(TM), Lausanne, Switzerland. The objective of this collaboration is to identify and...

2014-03-31 04:20:51

CAMBRIDGE, England, March 31, 2014 /PRNewswire/ -- Convergence Pharmaceuticals Holdings Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has entered into a research alliance with Evotec, a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology...

2014-03-28 12:22:00

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/8gxjqj/investigation ) has announced the addition of the "Investigation Report on China's Tiotropium Bromide Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) As the air becomes more contaminated, incidence of asthma and chronic obstructive pulmonary diseases also increases. Consequently, more market space is provided for relevant drug...

2014-03-28 08:27:23

Cardiologists also believe their patients' top concern is the fear of experiencing a clot that leads to a stroke; real-world challenges may influence treatment decisions RIDGEFIELD, Conn., March 28, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results from a new survey of cardiologists to understand their perceptions about anticoagulation, stroke risk reduction and goals for non-valvular atrial fibrillation (NVAF) therapy when prescribing warfarin or...

2014-03-24 20:23:52

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/skgh5l/investigation) has announced the addition of the "Investigation Report on China Telmisartan Market" [http://www.researchandmarkets.com/research/skgh5l/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll...

2014-03-24 08:28:21

Presentations to include research around antidote for dabigatran, a post-hoc analysis of data from the RE-LY® trial and data from the GLORIA(TM)-AF registry RIDGEFIELD, Conn., March 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that data from three company-sponsored PRADAXA studies will be presented at the American College of Cardiology 63(rd) Annual Scientific Session (ACC.14) in Washington, D.C., March 29 to 31, 2014. An oral presentation will...

2014-03-22 23:04:44

A new lawsuit was filed on March 19, by a widow in Pennsylvania Eastern District Court alleging that her husband died from renal failure and intracerebral hemorrhage caused by Pradaxa. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Pradaxa side effects. San Diego, CA (PRWEB) March 21, 2014 AttorneyOne.com, a recognized authority on law,...

2014-03-21 08:24:55

Positive opinion is based on data from one of the largest clinical registration programs in its class, involving more than 13,000 adults with type 2 diabetes RIDGEFIELD, Conn. and INDIANAPOLIS, March 21, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of empagliflozin, an...

2014-03-20 23:33:37

Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that John Olszewski of Boehringer Ingelheim USA will speak at Pharmica’s SharePoint Conference for the Life Sciences Industry on June 4th and 5th in Plymouth Meeting, PA. Plymouth Meeting, PA (PRWEB) March 20, 2014 As part of its continued service to the industry, Pharmica will host its 10th SharePoint conference in Plymouth Meeting, PA on June 4-5, 2014. The two day conference will...

2014-03-19 23:31:58

According to a Court Order filed in March 13, new sanctions were imposed on Boehringer Ingelheim for Pradaxa Multidistrict Litigation discovery abuses. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Pradaxa side effects. San Diego, CA (PRWEB) March 19, 2014 AttorneyOne.com, a recognized authority on law, updated the website recently and now,...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related